Clinical Outcomes and Patient Experience of Biosimilar to Biosimilar Infliximab Switching in Patients with Inflammatory Bowel Disease: A Prospective, Single-Centre, Phase IV Interventional Study with a Nested Qualitative Study

Table 2

Data from the subset who discontinued due to patient choice.

CD/UC	Duration in study (days)	CRP		FCP		IBD Control VAS		Disease activity score
		W0	ET	W0	ET	W0	ET	W0	ET
CD	37	2	2	1640	NA	95	50	1	3
CD	43	23	9	295	NA	75	50	4	5
CD	98	1	40	1	26	35	35	6	9
CD	119	1	15	4.5	NA	75	40	NA	3
CD	154	4	9	11	3.8	97	93	2	2
CD	155	6	5	299	11	30	10	4	8
CD	NA	1	NA	22	NA	50	NA	6	NA
UC	63	1	1	67	NA	100	95	0	0
UC	112	1	1	13	8.2	97	50	0	1
UC	138	4	3	59	44	77	32	3	3

NA = not available; ET = early termination.